TP53 and central nervous system cancer: In another study, Kaplan–Meier survival analysis of 512 glioma patients (248 with TP53 alterations, 264 without) showed that the TP53 altered group had a shorter median survival of 79.99 months as compared to the TP53 unaltered group with a median survival of 95.57 months, indicating that TP53 alterations are associated with poorer overall survival [100].